Is the price fair?
What ABT's price assumes
Abbott Laboratories trades at 31.9× earnings against 33.4× for the median Medical Devices name, cheaper than its own group.
31.9
Trailing P/E · Medical Devices median 33.4 · cheaper than the typical name in its group
- Price / sales
- 3.95
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.8%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +6.2%
Growth the price implies · The price pays for +6.2% free cash flow growth a year for a decade; the business has delivered +2.6% a year over the last three.
Details›
- Price / book2026-Q1
- 3.42
- EV / EBIT2026-Q1
- 26.1
- EV / sales2026-Q1
- 4.46
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $7.38B
- Market capitalisation
- $154.0B
- 3-year revenue growth
- +2.8%
- 3-year free cash flow growth
- +2.6%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $98.76 |
| Its own P/E history, median | $118.30 |
| Its own P/E history, upper quartile | $154.73 |
| 52-week range | $82.56 – $134.49 |
| Today | $114.10 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #16 of 35 by Smart Score